Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Short Interest Update

Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) saw a large drop in short interest in the month of June. As of June 30th, there was short interest totalling 163,300 shares, a drop of 25.2% from the June 15th total of 218,200 shares. Currently, 4.0% of the shares of the stock are sold short. Based on an average daily volume of 2,550,000 shares, the days-to-cover ratio is currently 0.1 days.

Institutional Investors Weigh In On Adial Pharmaceuticals

An institutional investor recently bought a new position in Adial Pharmaceuticals stock. Virtu Financial LLC acquired a new stake in Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) in the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund acquired 20,469 shares of the company’s stock, valued at approximately $27,000. Virtu Financial LLC owned about 0.48% of Adial Pharmaceuticals at the end of the most recent quarter. Institutional investors own 16.41% of the company’s stock.

Adial Pharmaceuticals Price Performance

ADIL opened at $1.13 on Friday. The stock’s fifty day moving average is $1.28 and its 200-day moving average is $1.48. Adial Pharmaceuticals has a one year low of $0.77 and a one year high of $8.88.

Adial Pharmaceuticals (NASDAQ:ADIL) last issued its earnings results on Tuesday, May 14th. The company reported ($0.68) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.17). As a group, equities research analysts predict that Adial Pharmaceuticals will post -1.66 earnings per share for the current fiscal year.

About Adial Pharmaceuticals

Adial Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder.